Previous Close | 8.29 |
Open | 8.28 |
Bid | 8.08 x 100 |
Ask | 8.19 x 500 |
Day's Range | 8.00 - 8.63 |
52 Week Range | 4.00 - 40.60 |
Volume | |
Avg. Volume | 650,302 |
Market Cap | 190.349M |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.00 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 39.91 |
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Compa
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European M